Nuclear Medicine and Biology
Volume 34, Issue 4 , Pages 353-361 , May 2007

PET Imaging of CRF1 with [11C]R121920 and [11C]DMP696: is the target of sufficient density?

  • Gregory M. Sullivan

      Affiliations

    • Division of Neuroscience, Department of Psychiatry, New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    • Corresponding Author InformationCorresponding author. Division of Neuroscience, Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA. Tel.: +1 212 543 6760; fax: +1 212 543 5437.
    • ,
  • Ramin V. Parsey

      Affiliations

    • Division of Neuroscience, Department of Psychiatry, New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    • ,
  • J.S. Dileep Kumar

      Affiliations

    • Division of Neuroscience, Department of Psychiatry, New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    • ,
  • Victoria Arango

      Affiliations

    • Division of Neuroscience, Department of Psychiatry, New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    • ,
  • Suham A. Kassir

      Affiliations

    • Division of Neuroscience, Department of Psychiatry, New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    • ,
  • Yung-yu Huang

      Affiliations

    • Division of Neuroscience, Department of Psychiatry, New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    • ,
  • Norman R. Simpson

      Affiliations

    • Division of Neuroscience, Department of Psychiatry, New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    • ,
  • Ronald L. Van Heertum

      Affiliations

    • Department of Radiology, Columbia University, New York, NY 10032, USA
    • ,
  • J. John Mann

      Affiliations

    • Division of Neuroscience, Department of Psychiatry, New York State Psychiatric Institute, Columbia University, New York, NY 10032, USA
    • Department of Radiology, Columbia University, New York, NY 10032, USA

Received 4 December 2006 ,Revised 29 January 2007 ,Accepted 29 January 2007.

References 

  1. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 1981;213:1394–1397
  2. De Souza EB. Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinology. 1995;20:789–819
  3. Behan DP, Grigoriadis DE, Lovenberg T, Chalmers D, Heinrichs S, Liaw C, et al. Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders. Mol Psychiatry. 1996;1:265–277
  4. Behan DP, De Souza EB, Lowry PJ, Potter E, Sawchenko P, Vale WW. Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides. Front Neuroendocrinol. 1995;16:362–382
  5. Grigoriadis DE, Lovenberg TW, Chalmers DT, Liaw C, De Souze EB. Characterization of corticotropin-releasing factor receptor subtypes. Ann N Y Acad Sci. 1996;780:60–80
  6. Heinrichs SC, De Souza EB, Schulteis G, Lapsansky JL, Grigoriadis DE. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology. 2002;27:194–202
  7. Chalmers DT, Lovenberg TW, Grigoriadis DE, Behan DP, De Souza EB. Corticotrophin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol Sci. 1996;17:166–172
  8. Hiroi N, Wong ML, Licinio J, Park C, Young M, Gold PW, et al. Expression of corticotropin releasing hormone receptors type I and type II mRNA in suicide victims and controls. Mol Psychiatry. 2001;6:540–546
  9. Sanchez MM, Young LJ, Plotsky PM, Insel TR. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol. 1999;408:365–377
  10. Aguilera G, Nikodemova M, Wynn PC, Catt KJ. Corticotropin releasing hormone receptors: two decades later. Peptides. 2004;25:319–329
  11. Banki CM, Bissette G, Arato M, O'Connor L, Nemeroff CB. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry. 1987;144:873–877
  12. Nemeroff CB, Widerlov E, Bissette G, Walleus H, Karlsson I, Eklund K, et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science. 1984;226:1342–1344
  13. Geracioti TD, Loosen PT, Orth DN. Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression. Biol Psychiatry. 1997;42:165–174
  14. Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, et al. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry. 1997;154:624–629
  15. Chappell P, Leckman J, Goodman W, Bissette G, Pauls D, Anderson G, et al. Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: comparison to obsessive compulsive disorder and normal controls. Biol Psychiatry. 1996;39:776–783
  16. Kaye WH, Gwirtsman HE, George DT, Ebert MH, Jimerson DC, Tomai TP, et al. Elevated cerebrospinal fluid levels of immunoreactive corticotropin-releasing hormone in anorexia nervosa: relation to state of nutrition, adrenal function, and intensity of depression. J Clin Endocrinol Metab. 1987;64:203–208
  17. Arato M, Banki CM, Bissette G, Nemeroff CB. Elevated CSF CRF in suicide victims. Biol Psychiatry. 1989;25:355–359
  18. Traskman-Bendz L, Ekman R, Regnell G, Ohman R. HPA-related CSF neuropeptides in suicide attempters. Eur Neuropsychopharmacol. 1992;2:99–106
  19. Brunner J, Stalla GK, Stalla J, Uhr M, Grabner A, Wetter TC, et al. Decreased corticotropin-releasing hormone (CRH) concentrations in the cerebrospinal fluid of eucortisolemic suicide attempters. J Psychiatr Res. 2001;35:1–9
  20. Westrin A, Ekman R, Regnell G, Traskman-Bendz L. A follow up study of suicide attempters: increase of CSF-somatostatin but no change in CSF-CRH. Eur Neuropsychopharmacol. 2001;11:135–143
  21. Austin MC, Janosky JE, Murphy HA. Increased corticotropin-releasing hormone immunoreactivity in monoamine-containing pontine nuclei of depressed suicide men. Mol Psychiatry. 2003;8:324–332
  22. Merali Z, Du L, Hrdina P, Palkovits M, Faludi G, Poulter MO, et al. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci. 2004;24:1478–1485
  23. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry. 1988;45:577–579
  24. McCarthy JR, Heinrichs SC, Grigoriadis DE. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Curr Pharm Des. 1999;5:289–315
  25. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res. 1999;33:181–214
  26. Keck ME, Welt T, Wigger A, Renner U, Engelmann M, Holsboer F, et al. The anxiolytic effect of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci. 2001;13:373–380
  27. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res. 2000;34:171–181
  28. Hsin LW, Webster EL, Chrousos GP, Gold PW, Eckelman WC, Contoreggi C, et al. Synthesis and biological activity of fluoro-substituted pyrrolo[2,3-d]pyrimidines: the development of potential positron emission tomography imaging agents for the corticotropin-releasing hormone type 1 receptor. Bioorg Med Chem Lett. 2000;10:707–710
  29. Hsin LW, Tian X, Webster EL, Coop A, Caldwell TM, Jacobson AE, et al. CRHR1 Receptor binding and lipophilicity of pyrrolopyrimidines, potential nonpeptide corticotropin-releasing hormone type 1 receptor antagonists. Bioorg Med Chem. 2002;10:175–183
  30. Tian X, Hsin LW, Webster EL, Contoreggi C, Chrousos GP, Gold PW, et al. The development of a potential single photon emission computed tomography (SPECT) imaging agent for the corticotropin-releasing hormone receptor type. Bioorg Med Chem Lett. 2001;11:331–333
  31. Martarello L, Kilts CD, Ely T, Owens MJ, Nemeroff CB, Camp M, et al. Synthesis and characterization of fluorinated and iodinated pyrrolopyrimidines as PET/SPECT ligands for the CRF1 receptor. Nucl Med Biol. 2001;28:187–195
  32. Jagoda E, Contoreggi C, Lee MJ, Kao CH, Szajek LP, Listwak S, et al. Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: synthesis of [(76)Br]MJL-1-109-2. J Med Chem. 2003;46:3559–3562
  33. Kumar JS, Majo VJ, Sullivan GM, Prabhakaran J, Simpson NR, Van Heertum RL, et al. Synthesis and in vivo evaluation of [11C]SN003: a potential PET ligand for CRF1 receptors. Bioorg Med Chem. 2006;14:4029–4034
  34. Wong DF, Pomper MG. Predicting the success of a radiopharmaceutical for in vivo imaging of central nervous system neuroreceptor systems. Mol Imaging Biol. 2003;5:350–362
  35. Kumar JS, Majo VJ, Prabhakaran J, Simpson NR, VanHeertum RL, Mann JJ. Synthesis of [N-methyl-11C]-3-[(6-dimethylamino)pyridin-3-yl]-2,5-dimethyl-N,N-dipropylpyrazolo[1,5-a]pyrimidine-7-amine: a potential PET ligand for CRF1 receptors. J Label Compd Radiopharm. 2003;46:1055–1065
  36. Kumar JS, Majo VJ, Simpson NR, Prabhakaran J, Van Heertum RL, Mann JJ. Synthesis of [O-methyl-11C]-4-(1,3-dimethoxy-2-propylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)[1,5-a]pyrazolo-1,3,5-triazine ([11C]DMP696): a potential PET ligand for CRF1 receptors. J Label Compd Radiopharm. 2004;47:971–976
  37. Zhang G, Huang N, Li YW, Qi X, Marshall AP, Yan XX, et al. Pharmacological characterization of a novel nonpeptide antagonist radioligand, (+/−)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor 1 receptors. J Pharmacol Exp Ther. 2003;305:57–69
  38. He L, Gilligan PJ, Zaczek R, Fitzgerald LW, McElroy J, Shen HS, et al. 4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist. J Med Chem. 2000;43:449–456
  39. Mackay KB, Bozigian H, Grigoriadis DE, Loddick SA, Verge G, Foster AC. Neuroprotective effects of the CRF1 antagonist R121920 after permanent focal ischemia in the rat. J Cereb Blood Flow Metab. 2001;21:1208–1214
  40. Parsey RV, Ojha A, Ogden RT, Erlandsson K, Kumar D, Landgrebe M, et al. Metabolite considerations in the in vivo quantification of serotonin transporters using 11C-DASB and PET in humans. J Nucl Med. 2006;47:1796–1802
  41. Woods RP, Grafton ST, Holmes CJ, Cherry SR, Mazziotta JC. Automated image registration: I. General methods and intrasubject, intramodality validation. J Comput Assist Tomogr. 1998;22:139–152
  42. Woods RP, Grafton ST, Watson JD, Sicotte NL, Mazziotta JC. Automated image registration: II. Intersubject validation of linear and nonlinear models. J Comput Assist Tomogr. 1998;22:153–165
  43. Parsey RV, Ogden RT, Mann JJ. Determination of volume of distribution using likelihood estimation in graphical analysis: elimination of estimation bias. J Cereb Blood Flow Metab. 2003;23:1471–1478
  44. Mintun MA, Raichle ME, Martin WR, Herscovitch P. Brain oxygen utilization measured with O-15 radiotracers and positron emission tomography. J Nucl Med. 1984;25:177–187
  45. Frey KA, Hichwa RD, Ehrenkaufer RL, Agranoff BW. Quantitative in vivo receptor binding III: tracer kinetic modeling of muscarinic cholinergic receptor binding. Proc Natl Acad Sci U S A. 1985;82:6711–6715
  46. Rominger DH, Rominger CM, Fitzgerald LW, Grzanna R, Largent BL, Zaczek R. Characterization of [125I]sauvagine binding to CRH2 receptors: membrane homogenate and autoradiographic studies. J Pharmacol Exp Ther. 1998;286:459–468
  47. Li YW, Hill G, Wong H, Kelly N, Ward K, Pierdomenico M, et al. Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy. J Pharmacol Exp Ther. 2003;305:86–96
  48. Millan MA, Jacobowitz DM, Hauger RL, Catt KJ, Aguilera G. Distribution of corticotropin-releasing factor receptors in primate brain. Proc Natl Acad Sci U S A. 1986;83:1921–1925
  49. Kostich WA, Grzanna R, Lu NZ, Largent BL. Immunohistochemical visualization of corticotropin-releasing factor type 1 (CRF1) receptors in monkey brain. J Comp Neurol. 2004;478:111–125
  50. Primus RJ, Yevich E, Baltazar C, Gallager DW. Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain. Neuropsychopharmacology. 1997;17:308–316
  51. Hoare SR, Sullivan SK, Ling N, Crowe PD, Grigoriadis DE. Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists. Mol Pharmacol. 2003;63:751–765
  52. Tokugawa J, Ravasi L, Nakayama T, Lang L, Schmidt KC, Seidel J, et al. Distribution of the 5-HT(1A) receptor antagonist [(18)F]FPWAY in blood and brain of the rat with and without isoflurane anesthesia. Eur J Nucl Med Mol Imaging. 2007;34:259–266
  53. Zeng Z, Chen TB, Miller PJ, Dean D, Tang YS, Sur C, et al. The serotonin transporter in rhesus monkey brain: comparison of DASB and citalopram binding sites. Nucl Med Biol. 2006;33:555–563

PII: S0969-8051(07)00039-X

doi: 10.1016/j.nucmedbio.2007.01.012

Nuclear Medicine and Biology
Volume 34, Issue 4 , Pages 353-361 , May 2007

Article Tools

* Image Usage & Resolution